Your search results will appear here.
Light Mode
Dark Mode
Sign Up
Sign In
Ultimovacs ASA logo

Ultimovacs ASA (7UM)

Market Open
25 Apr, 20:00
XSTU XSTU
XFRA XFRA Primary XMUN XMUN XOSL XOSL XDUS XDUS XBER XBER
€
1. 35
+0.09
+7%
€
- Market Cap
- P/E Ratio
0% Div Yield
0 Volume
-6 Eps
€ 1.26
Previous Close
Day Range
1.24 1.37
Year Range
0.96 8.79
Earnings results expected in 6 days

Summary

7UM trading today higher at €1.35, an increase of 7% from yesterday's close, completing a monthly decrease of -9.79% or €0.15. Over the past 12 months, 7UM stock lost -24.3%.
7UM is not paying dividends to its shareholders.
The last earnings report, released on Feb 13, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on May 05, 2025.
The stock of the company had never split.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on XFRA (EUR).
Want to track 7UM and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Get Started For Free

7UM Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.

Ultimovacs ASA (7UM) FAQ

What is the stock price today?

The current price is €1.35.

On which exchange is it traded?

Ultimovacs ASA is listed on XFRA.

What is its stock symbol?

The ticker symbol is 7UM.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 0.

When is the next earnings date?

The next earnings report will release on May 05, 2025.

Has Ultimovacs ASA ever had a stock split?

Ultimovacs ASA had 0 splits and the recent split was on Apr 01, 2025.

Ultimovacs ASA Profile

Biotechnology Industry
Healthcare Sector
Dr. Carlos de Sousa CEO
XSTU Exchange
NO0010851603 ISIN
NO Country
24 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Ultimovacs ASA is a pioneering biotech firm grounded in Oslo, Norway, with a mission to innovate in the realm of immunotherapies targeting various cancers. Since its incorporation in 2011, Ultimovacs has been at the forefront of developing novel treatments, focusing on harnessing the body's immune system to fight cancer. Their work revolves around creating vaccines that can train the immune system to recognize and eliminate cancer cells, aiming to provide a universal solution in the battle against this complex disease.

Products and Services

  • UV1 - Peptide-based Cancer Vaccine

    • Ultimovacs' flagship product, UV1, stands as a testament to their innovative approach towards cancer treatment. This peptide-based cancer vaccine is designed to elicit a strong and specific T cell response against telomerase, a universal cancer antigen found in over 85% of all cancers. By targeting telomerase, UV1 has the potential to be used across a wide array of cancer types, making it a versatile and groundbreaking approach in the field of oncology. The development of UV1 underpins Ultimovacs' commitment to improving patient outcomes and offering new hope in the fight against cancer.

Contact Information

Address: Ullernchausséen 64, Oslo, Norway, 0379
Phone: 47 41 38 00 80
Affiliate Program About Report a Bug Terms Privacy Help Contact Us
2025 © Marketlog. All Rights Reserved.
Play store app banner Play store app banner dark App store app banner App store app banner dark
Logo Logo
Sign Up
Sign In